ERBB2 and neoplasm: Large pooled analyses and subtype-specific neoadjuvant trials have shown that pCR is both more frequent and more strongly associated with improved event-free and overall survival in triple-negative and HER2-positive disease than in hormone receptor-positive, HER2-negative tumours [29,30,31].